Patents by Inventor Mark L. Lee

Mark L. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxy-[1-substituted carbonyl-2-(or 3-) piperidinyl methoxy]phosphinyloxy]-N,N,N-trialkylalkaneaminium hydroxide inner salt oxides having antitumor activity
    Patent number: 4749696
    Abstract: The invention discloses hydroxy-[1-substituted carbonyl-2-(or 3-) piperidinyl methoxy]phosphinyloxy]-N,N,N-trilkylalkaneaminium hydroxide inner salt oxides useful as antitumor agents, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for treating tumors.
    Type: Grant
    Filed: August 29, 1986
    Date of Patent: June 7, 1988
    Assignee: Sandoz Pharm. Corp.
    Inventor: Mark L. Lee
  • Substituted-[hydroxy(tetrahydro)-5-oxo-(2- and 3-furanyl or 2-thienyl)alkoxyphosphinyloxy]-alkanaminium hydroxide, inner salt oxides
    Patent number: 4673672
    Abstract: The invention discloses substituted 2-[hydroxy(tetrahydro)-5-oxo-(2- and 3-furanyl or 2-thienyl) alkoxyphosphinyloxy]-alkanaminium hydroxide inner salt-4-oxides useful as anti-tumor agents, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for treating tumors.
    Type: Grant
    Filed: June 17, 1986
    Date of Patent: June 16, 1987
    Assignee: Sandoz Pharmaceuticals Corp.
    Inventors: William J. Houlihan, Mark L. Lee
  • Substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts
    Patent number: 4619917
    Abstract: The invention discloses certain substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts useful as PAF inhibitors, pharmaceutical compositions containing said compounds as an active ingredient thereof and a method of using such compositions for inhibiting PAF-induced blood platelet aggregation, PAF-mediated bronchoconstriction and extravasation, PAF-induced hypotension and PAF-induced ischemic bowel disease.
    Type: Grant
    Filed: October 31, 1985
    Date of Patent: October 28, 1986
    Assignee: Sandoz Pharm. Corp.
    Inventors: Mark L. Lee, Christian Jaeggi